FIGURE 2.

Most rituximab‐treated patients with lymphoma lack antibody responses to Spike or receptor‐binding domain (RBD) after vaccination. (A–D) Relative levels of immunoglobulin G (IgG) antibodies after vaccination to full‐length (FL) Spike from severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) (y‐axis) and the RBD (x‐axis) in patients treated with anti‐CD20 monoclonal antibodies (mAbs) for B‐cell lymphoma (A) or multiple sclerosis (C), compared to healthy controls (B). Relative antibody levels are reported as arbitrary units (au) = (MFI_{viral protein beads})/(MFI_{no protein beads}). Each dot represents one individual. Blue dots indicate sera with antibody levels above the double cut‐off for RBD and FL Spike (au ≥5). (D) Anti‐RBD in patients according to days after last dose of treatment. Orange dots indicate patients on treatment, while grey squares indicate patients where treatment is terminated. MFI, median fluorescence intensity